propranolol has been researched along with Multiple Primary Neoplasms in 10 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Infantile hemangiomas are the most common vascular tumors in childhood." | 5.42 | Delayed-onset of multiple cutaneous infantile hemangiomas due to propranolol: a case report. ( del Boz González, J; Navarro Morón, J; Porcel Chacón, R, 2015) |
| "Infantile hemangiomas are benign vascular tumors that affect 8-12 % of infants." | 2.46 | [Propanolol used in treatment of infantile hemangioma]. ( Guldbakke, KK; Hanssen, HK; Huldt-Nystrøm, T; Høivik, F; Rørdam, OM, 2010) |
| "Subglottic hemangiomas are a rare presentation of infantile hemangiomas but with significant morbidity." | 1.48 | Subglottic hemangioma: Understanding the association with facial segmental hemangioma in a beard distribution. ( Azbell, C; Grunwaldt, L; Jabbour, N; McCormick, AA; Tarchichi, T, 2018) |
| "The patient has hypoxemia due to abdominal distention during the follow-up period." | 1.46 | Beta blocker and steroid therapy in the treatment of infantile hepatic hemangioendothelioma. ( Bör, Ö; Düzenli Kar, Y; Kebapçı, M; Özdemir, ZC; Şöhret, NC, 2017) |
| "Infantile hemangiomas are the most common vascular tumors in childhood." | 1.42 | Delayed-onset of multiple cutaneous infantile hemangiomas due to propranolol: a case report. ( del Boz González, J; Navarro Morón, J; Porcel Chacón, R, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Özdemir, ZC | 1 |
| Düzenli Kar, Y | 1 |
| Şöhret, NC | 1 |
| Kebapçı, M | 1 |
| Bör, Ö | 1 |
| McCormick, AA | 1 |
| Tarchichi, T | 1 |
| Azbell, C | 1 |
| Grunwaldt, L | 1 |
| Jabbour, N | 1 |
| Yang, K | 1 |
| Feng, L | 1 |
| Chen, S | 1 |
| Ji, Y | 1 |
| Miquel, J | 1 |
| Bruneau, B | 1 |
| Dupuy, A | 1 |
| Porcel Chacón, R | 1 |
| del Boz González, J | 1 |
| Navarro Morón, J | 1 |
| Guldbakke, KK | 1 |
| Rørdam, OM | 1 |
| Huldt-Nystrøm, T | 1 |
| Hanssen, HK | 1 |
| Høivik, F | 1 |
| Martínez-Escanamé, M | 1 |
| Castillo-Martínez, C | 1 |
| Torres-Álvarez, B | 1 |
| González, FJ | 1 |
| Oros-Valle, C | 1 |
| Moncada, B | 1 |
| Avagyan, S | 1 |
| Klein, M | 1 |
| Kerkar, N | 1 |
| Demattia, A | 1 |
| Blei, F | 1 |
| Lee, S | 1 |
| Rosenberg, HK | 1 |
| Arnon, R | 1 |
| Baranowski, S | 1 |
| Winkler, A | 1 |
| Kunzi-Rapp, K | 1 |
| Schaal, M | 1 |
| Hempel, S | 1 |
| Debatin, KM | 1 |
| Posovszky, C | 1 |
| Harrison, TS | 1 |
| Freier, DT | 1 |
| Cohen, EL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sirolimus in the Treatment for Propranolol-resistant Infantile Hepatic Hemangioendothelioma[NCT04406870] | Phase 4 | 36 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for propranolol and Multiple Primary Neoplasms
| Article | Year |
|---|---|
[Propanolol used in treatment of infantile hemangioma].
Topics: Adrenergic beta-Antagonists; Eye Neoplasms; Female; Hemangioma; Humans; Infant; Neoplasms, Multiple | 2010 |
9 other studies available for propranolol and Multiple Primary Neoplasms
| Article | Year |
|---|---|
Beta blocker and steroid therapy in the treatment of infantile hepatic hemangioendothelioma.
Topics: Adrenergic beta-Antagonists; Glucocorticoids; Hemangioendothelioma; Hepatomegaly; Humans; Hypothyroi | 2017 |
Subglottic hemangioma: Understanding the association with facial segmental hemangioma in a beard distribution.
Topics: Antineoplastic Agents; Combined Modality Therapy; Facial Neoplasms; Female; Hemangioma; Humans; Infa | 2018 |
Progressive infantile hepatic hemangioma not responding to propranolol.
Topics: Adrenergic beta-Antagonists; Age of Onset; Child, Preschool; Disease Progression; Fatal Outcome; Fem | 2019 |
Successful treatment of multifocal intracerebral and spinal hemangiomas with propranolol.
Topics: Brain Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; | 2014 |
Delayed-onset of multiple cutaneous infantile hemangiomas due to propranolol: a case report.
Topics: Dose-Response Relationship, Drug; Heart Defects, Congenital; Hemangioma; Humans; Infant; Infant, New | 2015 |
Diffuse neonatal hemangiomatosis: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrointestinal Neop | 2012 |
Propranolol as a first-line treatment for diffuse infantile hepatic hemangioendothelioma.
Topics: Adrenergic beta-2 Receptor Antagonists; Antineoplastic Agents; Congenital Hypothyroidism; Drug Monit | 2013 |
[Infantile hepatic hemangiomas: first-line propranolol monotherapy as new treatment strategy?].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Beckwith-Wiedemann Syndrome; Female; Follow-Up St | 2012 |
Proceedings: Recurrent pheochromocytoma.
Topics: Abdominal Neoplasms; Adolescent; Adrenal Gland Neoplasms; Adult; Child; Epinephrine; Female; Hormone | 1974 |